AIM ImmunoTech Announces Release of the Next CEO Corner Segment
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
OCALA, Fla., July 03, 2024 — AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company") today announced the next CEO Corner segment has been published on the Company's website. For the CEO Corner segment, AIM Chief Executive Officer Thomas Equels provided an update on the Phase 1b/2 "DURIPANC" study of Ampligen and AstraZeneca's Imfinzi as a combination therapy for late-stage pancreatic cancer. The Company also provided a business update, including that as a result of recent financings, AIM recently had stockholders' equity of $6.9 million.
2024年7月3日佛罗里达州奥卡拉市——AIM免疫技术公司（纽交所美国：AIM）（“AIM”或“公司”）今天宣布，下一期CEO角落环节已经刊登在公司的网站上。在CEO角落环节中，AIM首席执行官托马斯·伊奎尔斯（Thomas Equels）对于Ampligen和阿斯利康（AstraZeneca）的Imfinzi联合治疗晚期胰腺癌的1b/2期DURIPANC研究进行了更新。该公司还提供了业务更新，包括由于最近的融资，AIM最近的股东权益为690万美元。
The CEO Corner segment is now available here.
CEO角落现在可以在这里找到。
About AIM ImmunoTech Inc.
AIM Immunotech股份有限公司是一家免疫药品公司，专注于研究和开发治疗多种癌症、免疫性疾病和病毒性疾病（包括COVID-19）的治疗药物。该公司的主要产品是一种名为Ampligen（吡咯烷寡核苷酸）的首创调节免疫器官的药物，具有广泛的临床试验、覆盖全球重要癌症、病毒性疾病和免疫系统疾病的广谱活性。
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company's lead product is a first-in-class investigational drug called Ampligen (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.
AIM Immunotech公司是一家免疫药物公司，专注于研究和开发治疗多种癌症、免疫失调和病毒性疾病（包括COVID-19）的治疗药物。该公司的主要产品是一种名为Ampligen（Rintatolimod）的首创性调节免疫药物，是一种dsRNA和高选择性TLR3激动剂，广泛应用于针对全球重要癌症、病毒性疾病和免疫系统疾病的临床试验中。
For more information, please visit aimimmuno.com and connect with the Company on X, LinkedIn, and Facebook.
欲了解更多信息，请访问aimimmuno.com，并加入公司的X、LinkedIn和Facebook。
Investor Contact:
JTC Team, LLC
Jenene Thomas
(833) 475-8247
AIM@jtcir.com
投资者联系人：
JTC团队有限责任公司
Jenene Thomas
(833) 475-8247
AIM@jtcir.com
